Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc (LH) delivers essential clinical diagnostics and advanced laboratory solutions that shape modern medical decision-making. This dedicated news hub provides investors and healthcare professionals with timely updates on Labcorp's operational developments, scientific advancements, and strategic initiatives.
Access curated press releases and analysis covering earnings reports, partnership announcements, and innovations in precision oncology diagnostics. Track Labcorp's progress in genomic sequencing technologies and biopharma collaborations through verified updates from primary sources.
The resource consolidates critical information about Labcorp's laboratory network expansions, regulatory milestones, and service enhancements across clinical testing and drug development sectors. Users gain insights into how the company maintains its leadership through scientific rigor and operational scale.
Bookmark this page for streamlined access to Labcorp's evolving role in healthcare innovation, with updates organized for efficient navigation. Return regularly to stay informed about developments impacting diagnostic capabilities and research partnerships in the life sciences sector.
Labcorp (NYSE: LH) reported its Q1 2023 results, showing a 10% increase in Base Business revenue but a decline in total revenue to $3.8 billion from $3.9 billion last year. Diluted EPS dropped to $2.39 from $5.23, while adjusted EPS fell to $3.82 from $6.11. Free cash flow also decreased significantly to $27 million from $239 million. The company updated its full-year guidance, projecting adjusted EPS between $16.25 and $17.75 and free cash flow of $1.0 billion to $1.2 billion. The planned spin-off of its Clinical Development business, now named Fortrea, is on schedule for mid-2023. Overall, the results were mixed with notable declines in COVID-19 testing impacting revenue.
Labcorp (NYSE: LH) announced a quarterly cash dividend of $0.72 per share, payable on June 8, 2023. Stockholders of record as of the close of business on May 18, 2023 will receive this dividend. This decision underscores Labcorp's commitment to returning value to its shareholders. In FY2022, the company reported revenues of $14.9 billion, highlighting its strong financial performance in the life sciences sector. For more details, visit www.labcorp.com.
Labcorp has partnered with the Conference of National Black Churches to improve access to colorectal cancer screening in high-risk communities. Over 3,000 screening kits will be distributed across cities like Atlanta and Los Angeles. Colorectal cancer disproportionately affects the Black community, with a 20% higher incidence and 40% higher mortality rate compared to other groups. Despite the importance of screening, 62% of respondents in a recent survey have not been screened. Labcorp emphasizes the significance of early detection, offering convenient at-home testing options for patients.
Labcorp (NYSE: LH), a prominent global life sciences firm, will release its financial results for Q1 2023 on
FAQ
What is the current stock price of Labcorp Holdings (LH)?
What is the market cap of Labcorp Holdings (LH)?
